Can This Pharma Go From Good to Great?
Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?
Is It Time for GlaxoSmithKline plc to Change Management?
GlaxoSmithKline's share price has stagnated under CEO Andrew Witty. Is it time for a change?
Why Pfizer Inc. Isn't Built to Last
Pfizer may be about to break up. Here's what investors need to know.
This Exciting Biotech Isn't Built to Last
Acadia Pharmaceuticals' Parkinson's disease drug was guaranteed a speedy review and the attention of top FDA officials. So why did this company's stock recently tank so rapidly? There's a cautionary tale here for all biotech investors.